[HTML][HTML] Gain/amplification of chromosome arm 1q21 in multiple myeloma
I Hanamura - Cancers, 2021 - mdpi.com
Simple Summary Multiple myeloma (MM), a plasma cell neoplasm, is an incurable
hematological malignancy. Gain/amplification of chromosome arm 1q21 (1q21+) is the most …
hematological malignancy. Gain/amplification of chromosome arm 1q21 (1q21+) is the most …
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and …
F Gay, P Musto, D Rota-Scalabrini, L Bertamini… - The Lancet …, 2021 - thelancet.com
Background Bortezomib-based induction followed by high-dose melphalan (200 mg/m 2)
and autologous stem-cell transplantation (MEL200-ASCT) and maintenance treatment with …
and autologous stem-cell transplantation (MEL200-ASCT) and maintenance treatment with …
[HTML][HTML] Multiparametric flow cytometry for MRD monitoring in hematologic malignancies: clinical applications and new challenges
G Riva, V Nasillo, AM Ottomano, G Bergonzini… - Cancers, 2021 - mdpi.com
Simple Summary In hematologic cancers, Minimal Residual Disease (MRD) monitoring,
using either molecular (PCR) or immunophenotypic (MFC) diagnostics, allows the …
using either molecular (PCR) or immunophenotypic (MFC) diagnostics, allows the …
Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma
LJ Costa, S Chhabra, E Medvedova… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE The MASTER trial combined daratumumab, carfilzomib, lenalidomide, and
dexamethasone (Dara-KRd) in newly diagnosed multiple myeloma (NDMM), using minimal …
dexamethasone (Dara-KRd) in newly diagnosed multiple myeloma (NDMM), using minimal …
Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma
Y Wang, J Cao, W Gu, M Shi, J Lan, Z Yan… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE A combination of anti–B-cell maturation antigen (BCMA) and anti-CD19 chimeric
antigen receptor (CAR) T cells induced high response rates in patients with relapsed or …
antigen receptor (CAR) T cells induced high response rates in patients with relapsed or …
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial
LJ Costa, S Chhabra, E Medvedova… - The Lancet …, 2023 - thelancet.com
Background For patients with newly diagnosed multiple myeloma, reaching minimal residual
disease (MRD) negativity after treatment is associated with improved outcomes; however …
disease (MRD) negativity after treatment is associated with improved outcomes; however …
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple …
Background Lenalidomide is a cornerstone of maintenance therapy in patients with newly
diagnosed multiple myeloma after autologous stem-cell transplantation. We aimed to …
diagnosed multiple myeloma after autologous stem-cell transplantation. We aimed to …
Minimal residual disease in myeloma: application for clinical care and new drug registration
KC Anderson, D Auclair, SJ Adam, A Agarwal… - Clinical Cancer …, 2021 - AACR
The development of novel agents has transformed the treatment paradigm for multiple
myeloma, with minimal residual disease (MRD) negativity now achievable across the entire …
myeloma, with minimal residual disease (MRD) negativity now achievable across the entire …
MRD assessment in multiple myeloma: progress and challenges
L Bertamini, M D'Agostino, F Gay - Current hematologic malignancy …, 2021 - Springer
Abstract Purpose of Review Over the last decade, the development of effective treatment
approaches for multiple myeloma (MM) has been associated with higher response rates and …
approaches for multiple myeloma (MM) has been associated with higher response rates and …
Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN
PM Voorhees, C Rodriguez, B Reeves… - Blood …, 2021 - ashpublications.org
The phase 2 GRIFFIN study of daratumumab plus lenalidomide/bortezomib/dexamethasone
(D-RVd) for transplant-eligible, newly diagnosed multiple myeloma included a safety run-in …
(D-RVd) for transplant-eligible, newly diagnosed multiple myeloma included a safety run-in …